INOVIQ'S NEW CANCER TREATMENT KILLS 88% OF BREAST AND LUNG CANCER CELLS IN LAB TESTS
INOVIQ Ltd (ASX:IIQ)
INOVIQ Limited (ASX: IIQ) is pleased to announce a major milestone in its exosome therapeutic program. In recent in vitro studies, INOVIQ’s CAR-exosomes demonstrated exceptional efficacy, killing 88% of TNBC and lung cancer cells within 96 hours.
This marks a major success for INOVIQ’s new platform, showing it works well against two solid tumours.
The treatment:
- Uses engineered immune cell particles called CAR-NK-EVs;
- These particles are designed to target and kill cancer cells more precisely; and
- INOVIQ uses a special method called EXO-ACE™ to produce and purify these particles for quality and shelf life.
Going forward this could lead to an ‘off the shelf’ therapy made in advance and used on many patients – unlike other treatments that must be customised.
It could be:
- Faster to produce;
- Safer to use; and
- More effective than traditional cell therapies like CAR-T.
The treatment will now be tested in mice to see how it works in living systems. Animal studies are the next step before human clinical trials.
CSO Prof Greg Rice said: “Our exosome therapeutic platform has now been validated demonstrating its potential to deliver transformative “off-the-shelf” therapies. Our platform offers potential cost, safety and efficacy advantages over traditional CAR-T cell therapies, enabling development of targeted therapeutics for multiple cancer types.”
Company Chair, Mr David Williams added: “These results move us closer to delivering life-changing treatments for cancer patients.”
Key Facts:
INOVIQ has developed a new cancer treatment using exosomes – tiny particles that help deliver targeted therapies.
In lab studies, this treatment destroyed 88% of cells from two aggressive cancers, Triple negative breast cancer (TNBC) and Lung Cancer.
About us:
INOVIQ Ltd (ASX: IIQ) is a leader in exosome technology focused on advancing next-generation diagnostics and therapeutics that transform cancer care and improve patient outcomes. Our product portfolio spans commercial-stage exosome isolation products, clinical-stage diagnostics for ovarian and breast cancers, and a cutting-edge preclinical-stage CAR-exosome therapeutic program targeting solid tumours such as TNBC and lung cancer. Through scientific excellence and innovation, INOVIQ is shaping the future of cancer detection and treatment. For more information on INOVIQ, visit www.inoviq.com.
Contact details:
Dr Leearne Hinch, Chief Executive Officer
M +61 400 414 416
